Home›Nutrition & Obesity Medicine› Marine compounds from Mexican Pacific Sargassum may protect against AMD progression in preclinical models
Marine compounds from Mexican Pacific Sargassum may protect against AMD progression in preclinical modelsMarine compounds from seaweed may protect eyes from age-related degeneration
Frontiers in MedicinePublished August 6, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider marine Sargassum compounds as investigational, not clinically proven, for AMD prevention.
This narrative review summarizes the potential of marine-derived bioactive compounds from Mexican Pacific Sargassum, specifically fucoxanthin, fucoidans, phlorotannins, and polyunsaturated fatty acids, in the context of age-related macular degeneration (AMD). The review is based on preclinical models and does not report any clinical trial data.
The authors synthesize evidence suggesting these compounds may exert protective effects against AMD progression through multipronged regulation of redox and inflammatory pathways. Secondary outcomes include modulation of oxidative stress, Nrf2/HO-1 signaling, NF-κB-mediated inflammation, VEGF-associated angiogenesis, mitochondrial dysfunction, and apoptosis in retinal cells.
However, the review does not provide effect sizes, absolute numbers, or statistical significance for these outcomes. The evidence is derived from preclinical models, and the authors explicitly note that results are not clinically established.
Key limitations highlighted include bioavailability issues, extraction standardization, safety concerns, and the absence of AMD-specific clinical trials. The authors do not report any adverse events, serious adverse events, or discontinuations.
Practice relevance is limited to potential development of nutraceutical strategies targeting retinal degeneration and AMD, but the authors caution that these applications are promising yet underexplored. Clinicians should interpret these findings as hypothesis-generating rather than actionable for patient care.
How this fits prior evidence
This narrative review extends prior coverage on AMD risk factors and treatments by exploring a novel preventive avenue. It complements findings on genetic (CFH Y402H, ARMS2 A69S) and modifiable risk factors (age, smoking) by suggesting marine compounds may modulate pathways implicated in AMD. It also contrasts with established therapies like faricimab by focusing on nutraceutical strategies, though it lacks clinical data. The review addresses a gap in dietary interventions but remains preclinical, so it does not yet confirm or refute prior evidence.
Age-related macular degeneration can slowly steal a person's vision as they get older. Researchers are looking for ways to protect the retina, the light-sensitive tissue at the back of the eye. They recently reviewed how certain compounds found in Mexican Pacific Sargassum seaweed might help fight this condition.
These marine-derived substances include fucoxanthin and phlorotannins. In early laboratory models, these compounds appeared to protect retinal cells by targeting inflammation and oxidative stress. Specifically, they may help manage the pathways that lead to cell death and tissue damage in the eye.
While these results are promising for future treatments, it is important to note that this research was done in preclinical models, not in humans. There are still hurdles to clear, such as ensuring the body can absorb these compounds effectively and confirming their safety in people. No clinical trials have been conducted yet.
What this means for you:
Marine-derived seaweed compounds show promise in lab tests for protecting eyes from age-related degeneration.
Common questions
What is the role of these seaweeds in eye health?
The study looked at bioactive compounds like fucoxanthin and phlorotannins found in Mexican Pacific Sargassum. These compounds may protect retinal cells by regulating inflammation and oxidative stress, which are key factors in the progression of age-related macular degeneration.
Is this treatment currently available for patients?
No, these results are not yet established for human use. The study was based on preclinical models, meaning it was tested in a laboratory setting. There are no clinical trials available to confirm if these compounds work or are safe for people with macular degeneration.
What challenges remain before these compounds can be used as medicine?
Several hurdles remain, including concerns about how well the body can absorb these compounds (bioavailability) and the need to standardize how they are extracted. Because no human trials have been conducted yet, their safety for people is not currently known.
Age-related macular degeneration (AMD) is a multifactorial retinal neurodegenerative disease characterized by oxidative stress, chronic inflammation, retinal pigment epithelium (RPE) dysfunction, and progressive central vision loss. Marine-derived bioactive compounds from Mexican Pacific Sargassum species have emerged as promising nutraceutical candidates due to their antioxidant, anti-inflammatory, and cytoprotective properties. This narrative review critically examines the nutritional composition and pharmacologically relevant bioactive constituents of Mexican Pacific Sargassum, with emphasis on fucoxanthin, fucoidans, phlorotannins, and polyunsaturated fatty acids. Particular attention is given to their molecular mechanisms of action in AMD-related pathways, including modulation of oxidative stress, Nrf2/HO-1 signaling, NF-κB-mediated inflammation, VEGF-associated angiogenesis, mitochondrial dysfunction, and apoptosis in retinal cells. Current evidence from preclinical retinal models suggests that these compounds may exert protective effects against AMD progression through multipronged regulation of redox and inflammatory pathways. Additionally, major translational challenges related to bioavailability, extraction standardization, safety, and the absence of AMD-specific clinical trials are critically discussed. Overall, Mexican Pacific Sargassum represents a promising yet underexplored source of marine bioactives with potential applications in the development of nutraceutical strategies targeting retinal degeneration and AMD.
